Group 1: Export Control Measures - The Ministry of Commerce of China has announced a ban on the export of all dual-use items to military users in Japan, as well as any other end-users that may enhance Japan's military capabilities, in accordance with the Export Control Law of the People's Republic of China [1] Group 2: Stock Market Performance - On January 6, the Shanghai Composite Index achieved a record of 13 consecutive days of gains, marking the longest streak in its history [2][9] - The index rose by 1.50% on January 6, with over 4,100 stocks increasing in value and a trading volume exceeding 2.8 trillion yuan [14] Group 3: Monetary Policy - The People's Bank of China emphasized the continuation of a moderately loose monetary policy during its work meeting held on January 5-6, aiming to enhance financial services for high-quality economic development and stabilize market expectations [4][11] Group 4: Market Sector Analysis - The brain-computer interface sector has seen significant growth, with multiple stocks reaching their daily limit up, including Sanbo Brain Science and Weisi Medical [14] - The non-ferrous metals and chemical sectors also performed strongly, with Zijin Mining's A-share market capitalization surpassing 100 billion yuan, achieving a historical high [14]

北京商报讯（记者 丁宁）1月6日晚间，亚辉龙（688575）发布公告称，公司于近日与深圳脑机星链科 技有限公司（以下简称"脑机星链"）签署了《战略合作框架协议》，双方共同达成战略合作，通过整合 脑机接口技术与临床和市场资源，共同开发脑机接口相关在研产品及推进后续市场拓展及推广，提升在 中枢神经疾病等领域诊疗技术水平。 亚辉龙表示，脑机星链是一家以人工智能为核心驱动力，深耕非侵入式与侵入式双技术路径的脑机接口 领域企业，通过脑机接口应用平台(神经解码软件、超柔性多通道电极、应用芯片)与神经调控技术深度 结合，加速阿尔茨海默症、孤独症、抑郁症、脑疾病神经类疾病检测与诊断产品落地，形成横跨硬件终 端、算法模型与云端服务的三位一体架构。目前已开发有脑电采集分析仪、脑机接口助眠仪、脑机接口 睡眠监测仪、迷走神机刺激仪等产品。本次战略合作，将结合双方的优势，有利于提升公司在中枢神经 疾病等领域竞争力以及拓展公司在脑机接口相关领域的战略布局，符合公司长远发展战略和全体股东的 利益。 ...

Core Viewpoint - The medical sector is experiencing significant activity, particularly driven by advancements in brain-computer interface (BCI) technology, which is attracting investor interest and leading to substantial market movements in related stocks and ETFs [3][10][11]. Market Performance - On January 6, 2026, the largest medical ETF (512170) saw a recovery, closing up 1.12% with a total trading volume of 1.017 billion yuan, marking two consecutive days of trading over 1 billion yuan [1][8]. - The ETF's index, which includes 12 related concept stocks, has a combined weight exceeding 36%, indicating strong sector representation [11][13]. Stock Highlights - Brain-computer interface stocks, such as Sanbo Brain Science and Meihua Medical, reached their daily limit up, while stocks like Yingke Medical and Hejing Biological experienced declines [1][8]. - The BCI sector is expected to see increased valuations for related listed companies, potentially boosting market financing and capital development [3][10]. Technological Advancements - A recent breakthrough in BCI technology was reported by Fudan University Huashan Hospital, which successfully completed the first clinical trial of a fully implanted, wireless, and functional BCI product [3][10]. - The BCI technology is positioned as a key area of investment, with potential applications in disease treatment and long-term enhancements for humans, opening up a market space worth trillions [10][11]. Investment Insights - According to CITIC Construction Investment, the current valuation of the medical index is 34.28 times, which is below the 70% threshold of the past decade, suggesting a favorable investment opportunity [4][11]. - The medical ETF (512170) is recognized as an efficient tool for accessing core medical assets, with a total size exceeding 26.4 billion yuan, making it the largest medical ETF in the market [6][13].

Group 1 - The core viewpoint of the news highlights a significant rise in technology-related stocks, particularly in commercial aerospace, brain-computer interface concepts, photovoltaic, chips, and semiconductor sectors, with the STAR Market indices showing positive performance [1] - The STAR 50 Index increased by 1.8%, while the STAR 100 Index and STAR Composite Index both rose by 1.5%, and the STAR Growth Index saw a 0.7% increase [1] - According to Wind data, the E Fund STAR 50 ETF (588080) experienced a net inflow of nearly 300 million yuan over two consecutive trading days [1] Group 2 - China Galaxy Securities anticipates that the reform policy expectations will strengthen in the first year of the 14th Five-Year Plan, with factors such as the upward trend of the RMB exchange rate supporting liquidity and boosting market confidence [1] - The report emphasizes the importance of focusing on technology leaders with performance realization capabilities under the logic of profit recovery [1]

Group 1 - The core viewpoint of the article emphasizes the importance of timely and relevant research reports in identifying investment opportunities, particularly in emerging fields like brain-computer interfaces [1] - Neuralink, led by Elon Musk, is set to begin large-scale production of brain-computer interface devices in 2026, marking a significant milestone in the integration of life sciences and information technology [1] - The brain-computer interface sector is experiencing rapid technological advancements and policy support, with expectations for commercialization to expand into AI applications and robotics by 2026 [1] Group 2 - The article highlights five key focus areas for investment as the humanoid robot sector approaches critical production milestones, with supply chains becoming more consolidated [2] - The AI wave is driving significant increases in storage prices, with DRAM prices soaring by 171.8%, while domestic wafer manufacturers are accelerating "domestic substitution" in response to tightening overseas restrictions [2] - New policies in Guangdong are encouraging insurance capital to enter the market, providing a dual boost to insurance stocks through asset and liability management [2] - A major state-owned enterprise has invested 1 billion in Thunderbird Innovation, signaling an imminent explosion in the AI glasses sector [2]

Core Viewpoint - The A-share market continues to strengthen, reaching a 10-year high, while the China Convertible Bond Index has also risen, hitting its highest point since June 2015 [1][3]. Group 1: Market Performance - The China Convertible Bond Index has shown a strong performance since 2025, highlighting its unique value in the equity market's volatility, characterized by "offensive and defensive" capabilities [2]. - On January 6, the China Convertible Bond Index surged by 1.35% to 505.77 points, marking a high not seen since June 2015 [4]. - The recent strong performance of convertible bonds is driven by the underlying stocks, with notable examples including the Seer Medical bond, which saw a 20% increase due to the stock's performance [5]. Group 2: Key Catalysts - The core catalyst for the current market rally is the commercialization breakthrough in the brain-computer interface industry, with significant announcements from companies like Neuralink [4]. - Domestic policy support for the brain-computer interface sector is also increasing, with initiatives aimed at expediting the approval processes for related medical devices [4]. Group 3: Structural Trends - The recent rally in convertible bonds is characterized by two main features: strong performance of underlying stocks and concentrated thematic interest in sectors like brain-computer interfaces and AI healthcare [5]. - Despite some convertible bonds experiencing declines due to falling stock prices, the overall market sentiment remains positive, driven by high-growth sectors [6]. Group 4: Historical Context - The last time the China Convertible Bond Index reached a historical high was in June 2015, during a peak in the A-share bull market [8]. - Since 2019, the convertible bond market has gradually recovered, with a notable resurgence in 2025, reflecting a strong correlation with the performance of underlying stocks [9]. Group 5: Future Outlook - Analysts suggest that the upcoming "spring rally" in the A-share and convertible bond markets may be influenced by seasonal capital inflows and policy expectations [12]. - The performance of convertible bonds in the near term will depend on institutional investment behavior and the release of annual performance forecasts for A-shares [12].

Core Viewpoint - The China Convertible Bond Index has reached a new high not seen in over a decade, reflecting its unique value in the volatile equity market, characterized by both offensive and defensive capabilities [1][2]. Group 1: Market Performance - On January 6, the China Convertible Bond Index surged by 1.35% to 505.77 points, marking the highest level since June 2015 [2]. - The recent performance of the index has been strong since 2025, highlighting its resilience amid fluctuations in the equity market [1][2]. - The strong performance of convertible bonds is closely linked to the performance of underlying stocks, with the index showing a rise of 18.66% in 2025, slightly outperforming the Shanghai Composite Index's 18.41% increase [5]. Group 2: Key Drivers - The core catalyst for the current market rally is the commercialization breakthrough in the brain-computer interface industry, with significant announcements from companies like Neuralink [3]. - Domestic policy support has intensified, with regulatory bodies accelerating the approval processes for related medical devices [3]. - Notable convertible bonds such as the Seli Convertible Bond have seen substantial gains, driven by the strong performance of their underlying stock, Seli Medical, which has been favored due to its advancements in AI and medical data [2][3]. Group 3: Market Trends and Analysis - Analysts have identified two main characteristics of the current convertible bond rally: the clear influence of underlying stock performance and the concentration of investment in high-growth sectors such as brain-computer interfaces and AI healthcare [3]. - The convertible bond market is experiencing a structural rally, with several bonds showing gains exceeding 10% [3]. - The market sentiment is expected to improve further due to seasonal capital inflows and policy expectations, potentially leading to a "spring rally" in the A-share and convertible bond markets [7].

人民财讯1月6日电，二连板麦澜德(688273)1月6日披露股票交易异动公告称，截至目前，公司在脑机接 口领域的产品尚处于研发及市场培育期，尚未实现规模化销售，暂未对公司业绩产生重大影响。技术路 线上，公司主要聚焦于非侵入式脑机接口技术的研发和产品化，与当前国际主流的侵入式脑机接口存在 显著技术路径差异。 ...

每经AI快讯，1月6日，麦澜德(688273.SH)发布股票交易异常波动公告称，截至目前，公司在脑机接口 领域的产品尚处于研发及市场培育期，尚未实现规模化销售，暂未对公司业绩产生重大影响。技术路线 上，公司主要聚焦于非侵入式脑机接口技术的研发和产品化，与当前国际主流的侵入式脑机接口存在显 著技术路径差异。 ...

Group 1 - The core point of the article is that Lens Technology (蓝思科技) is a strategic investor in Strong Brain Technology (强脑科技) and is set to mass-produce core hardware modules for brain-machine interface devices by 2026 [2] - Lens Technology has a long-term partnership of over 10 years with a major North American client, serving as a primary core supplier [2] - The company has accumulated mass production experience and strong precision manufacturing capabilities through projects like Strong Brain Technology, actively seeking further collaborations [2] Group 2 - In November 2025, Lens Technology and Strong Brain Technology plan to donate a large number of intelligent bionic limbs to the Hunan Provincial Disabled Persons' Federation, with all core modules sourced from Lens Technology's production line [2]